Blue Fin Capital Inc. Boosts Holdings in Amgen Inc. (NASDAQ:AMGN)

Blue Fin Capital Inc. grew its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 30.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,142 shares of the medical research company's stock after buying an additional 1,431 shares during the quarter. Blue Fin Capital Inc.'s holdings in Amgen were worth $1,601,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Centricity Wealth Management LLC bought a new stake in Amgen during the fourth quarter worth $25,000. Ritter Daniher Financial Advisory LLC DE increased its position in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in Amgen during the fourth quarter worth about $34,000. Atala Financial Inc bought a new position in Amgen in the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC bought a new position in Amgen in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AMGN. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price target on the stock. Mizuho raised their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Cantor Fitzgerald started coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price on the stock. Finally, Royal Bank of Canada cut their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Trading Up 2.3%

AMGN stock traded up $6.26 on Tuesday, reaching $277.92. The company's stock had a trading volume of 1,081,538 shares, compared to its average volume of 2,789,417. The business has a fifty day simple moving average of $285.94 and a two-hundred day simple moving average of $285.86. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market cap of $149.44 billion, a PE ratio of 36.76, a PEG ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.96 earnings per share. As a group, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.43%. Amgen's payout ratio is 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.